Hepatic Disorders and Covid-19: From Pathophysiology to Treatment Strategy Publisher Pubmed



Shiri Aghbash P^{1, 2} ; Ebrahimzadeh Leylabadlo H³ ; Fathi H^{2, 4} ; Bahmani M^{2, 5} ; Chegini R⁶ ; Bannazadeh Baghi H^{1, 2, 7}
Source: Canadian Journal of Gastroenterology and Hepatology Published:2022

Abstract

Following the SARS-CoV-2 outbreak and the subsequent development of the COVID-19 pandemic, organs such as the lungs, kidneys, liver, heart, and brain have been identified as priority organs. Liver diseases are considered a risk factor for high mortality from the COVID-19 pandemic. Besides, liver damage has been demonstrated in a substantial proportion of patients with COVID-19, especially those with severe clinical symptoms. Furthermore, antiviral medications, immunosuppressive drugs after liver transplantation, pre-existing hepatic diseases, and chronic liver diseases such as cirrhosis have also been implicated in SARS-CoV-2-induced liver injury. As a result, some precautions have been taken to prevent, monitor the virus, and avoid immunocompromised and susceptible individuals, such as liver and kidney transplant recipients, from being infected with SARS-CoV-2, thereby avoiding an increase in mortality. The purpose of this review was to examine the impairment caused by SARS-CoV-2 infection and the impact of drugs used during the pandemic on the mortality range and therefore the possibility of preventive measures in patients with liver disease. © 2022 Parisa Shiri Aghbash et al.